We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Places Clinical Hold on Scynexis’ IV Antifungal, Lifts Hold on Seattle Genetics AML Treatment
FDA Places Clinical Hold on Scynexis’ IV Antifungal, Lifts Hold on Seattle Genetics AML Treatment
The FDA has asked Scynexis to hold new clinical studies of an intravenous formulation of its antifungal treatment, SCY-078, until the agency can review available pre-clinical and clinical data.